Shuttle Pharmaceuticals Applauds Utah's AI Prescription Refill System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 Jan 26
Source: Yahoo Finance
Shuttle Pharmaceuticals Holdings Inc. saw a significant price increase of 22.70% in pre-market trading as the stock crossed above its 20-day SMA. The company applauded Utah's innovative AI prescription refill system, which allows AI to authorize refills without physician involvement, enhancing healthcare efficiency. This advancement aligns with Shuttle Pharma's own AI-driven Molecule.ai platform, which accelerates drug discovery and reduces costs, potentially transforming the industry and influencing future AI healthcare policies.
Analyst Views on SHPH
About SHPH
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
